Tagrisso predicted to lead small molecule lung cancer market

11 October 2023

Small molecule drugs are carving a significant niche in lung cancer treatment, an area in which AstraZeneca (LSE: AZN) achieved a landmark approval from the US Food and Drug Administration (FDA) following the results of the Phase III AURA trial.

The 2015 approval of Tagrisso (osimertinib) marked a significant advancement in the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).

Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio, with anticipated sales expected to surpass $7 billion and a 48% market share of small molecules in lung cancer treatment by 2029, according to GlobalData.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK